Free Trial
NASDAQ:RPRX

Royalty Pharma (RPRX) Stock Price, News & Analysis

$27.11
-0.06 (-0.22%)
(As of 09:34 AM ET)
Today's Range
$27.08
$27.16
50-Day Range
$27.17
$30.45
52-Week Range
$25.92
$34.65
Volume
36,494 shs
Average Volume
2.67 million shs
Market Capitalization
$16.20 billion
P/E Ratio
20.23
Dividend Yield
3.10%
Price Target
$46.75

Royalty Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
72.1% Upside
$46.75 Price Target
Short Interest
Healthy
3.59% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
1.35mentions of Royalty Pharma in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
9.18%
From $4.03 to $4.40 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.88 out of 5 stars

Finance Sector

34th out of 855 stocks

Pharmaceutical Preparations Industry

12th out of 421 stocks

RPRX stock logo

About Royalty Pharma Stock (NASDAQ:RPRX)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

RPRX Stock Price History

RPRX Stock News Headlines

7 Dividend Stocks to Buy at a 52-Week Low
Q1 2024 Royalty Pharma PLC Earnings Call
Royalty Pharma Beats Q1 Earnings and Revenue Estimates
Royalty Pharma declares $0.21 dividend
Royalty Pharma Declares Second Quarter 2024 Dividend
Royalty Pharma Declares Second Quarter 2024 Dividend
Relative Strength Alert For Royalty Pharma
See More Headlines
Receive RPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/15 Dividend
2/15/2024
Dividend Payable
3/15/2024
Last Earnings
5/09/2024
Ex-Dividend for 6/14 Dividend
5/16/2024
Today
5/21/2024
Dividend Payable
6/14/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Finance
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:RPRX
CUSIP
76028H20
Fax
N/A
Employees
51
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$46.75
High Stock Price Target
$57.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+72.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$1.13 billion
Pretax Margin
53.03%

Debt

Sales & Book Value

Annual Sales
$2.36 billion
Cash Flow
$4.55 per share
Book Value
$16.88 per share

Miscellaneous

Free Float
485,595,000
Market Cap
$16.23 billion
Optionable
Optionable
Beta
0.47

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Pablo Gerardo Legorreta (Age 59)
    Founder, Chairman of the Board & CEO
  • Mr. Terrance P. Coyne
    Executive VP & CFO
  • Mr. George Wingate Lloyd (Age 64)
    Executive VP of Investments & Chief Legal Officer
    Comp: $4.35M
  • Mr. Christopher Hite (Age 57)
    Vice Chairman & Executive VP
    Comp: $4.35M
  • Dr. Marshall Jonathan Urist M.D.
    Ph.D., Executive VP and Head of Research & Investments
  • Mr. Arthur Richard McGivern J.D.
    Executive Vice President of Investments & General Counsel
  • Mr. Ashwin Pai M.D.
    Executive Vice President of Investments
  • Ms. Kristin Stafford (Age 41)
    Senior VP & Chief Accounting Officer
  • Mr. Eric Cornelius Schneider
    Senior VP & Chief Technology Officer
  • Dr. James Folmar Reddoch Ph.D. (Age 54)
    Executive VP of Investments & Chief Scientific Officer
    Comp: $3.4M

RPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Royalty Pharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPRX shares.
View RPRX analyst ratings
or view top-rated stocks.

What is Royalty Pharma's stock price target for 2024?

4 analysts have issued twelve-month price targets for Royalty Pharma's shares. Their RPRX share price targets range from $38.00 to $57.00. On average, they expect the company's share price to reach $46.75 in the next year. This suggests a possible upside of 72.1% from the stock's current price.
View analysts price targets for RPRX
or view top-rated stocks among Wall Street analysts.

How have RPRX shares performed in 2024?

Royalty Pharma's stock was trading at $28.09 at the start of the year. Since then, RPRX stock has decreased by 3.3% and is now trading at $27.17.
View the best growth stocks for 2024 here
.

When is Royalty Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our RPRX earnings forecast
.

How were Royalty Pharma's earnings last quarter?

Royalty Pharma plc (NASDAQ:RPRX) posted its earnings results on Thursday, May, 9th. The biopharmaceutical company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.02. The biopharmaceutical company earned $568 million during the quarter, compared to analysts' expectations of $671.45 million. Royalty Pharma had a trailing twelve-month return on equity of 22.94% and a net margin of 35.70%. During the same period in the prior year, the firm earned $1.60 earnings per share.

How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?

Royalty Pharma declared a quarterly dividend on Wednesday, April 17th. Stockholders of record on Friday, May 17th will be paid a dividend of $0.21 per share on Friday, June 14th. This represents a $0.84 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date is Thursday, May 16th.
Read our dividend analysis for RPRX
.

Is Royalty Pharma a good dividend stock?

Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.84 per share and currently has a dividend yield of 3.06%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 62.69%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RPRX will have a dividend payout ratio of 19.09% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RPRX.

What other stocks do shareholders of Royalty Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO).

When did Royalty Pharma IPO?

Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at a price of $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

Who are Royalty Pharma's major shareholders?

Royalty Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.31%), Baillie Gifford & Co. (2.79%), Swedbank AB (1.39%), Homestead Advisers Corp (0.32%), Mitsubishi UFJ Trust & Banking Corp (0.31%) and Janus Henderson Group PLC (0.31%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Avara Management Ltd, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Scientific Corp Boston and Terrance P Coyne.
View institutional ownership trends
.

How do I buy shares of Royalty Pharma?

Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPRX) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners